# Andrew Jonathan Hillman Dallas senior paralegal and healthcare compliance expert witness Press releases carried by - The Tennessean - Yahoo Finance - EIN Presswire Andrew Jonathan Hillman is a Dallas Senior Paralegal and Healthcare Compliance Expert Witness. He is retained through counsel in federal matters nationwide, drawing on three decades of prior healthcare operations before closing that operating career. His expert-witness practice is active. - Regulatory compliance - Internal investigations - Litigation support - Expert witness ## Andrew Hillman. Andrew Jonathan Hillman is a Dallas senior paralegal and healthcare compliance and regulatory expert witness, retained through counsel in federal matters nationwide, drawing on three decades of prior experience building and operating FDA-regulated healthcare companies before closing that operating career. His expert-witness practice is active. He maintains a private family office, Hillman Ventures, whose activities are kept private. Born and raised in Oak Cliff and South Dallas, he started working at six and finished high school at Highland Park, a self-made arc that still shapes how he builds. He has since completed Harvard online courses in Jewish studies. ## Where the work concentrates. Four areas define the practice today, each grounded in three decades of healthcare operations and compliance. ### Regulatory governance and compliance Policy lifecycle management, SOP drafting, board reporting, and internal controls, conducted under retaining counsel. ### Internal audit and investigations Triage, document-retention playbooks, and internal compliance review across Stark, Anti-Kickback, and HIPAA matters, under counsel. ### Litigation and defense support Evidentiary review, subpoena compliance, and expert-report support for white-collar and regulatory defense, under retaining counsel. ### Expert witness engagements Operator testimony on healthcare operations and compliance, retained through counsel in federal matters nationwide. ## Essays on building in biotech and healthcare. Selected writing on commercialization, the FDA pathway, manufacturing, and the science behind modern medicine. ### Why most biotech startups fail The real reasons behind commercialization breakdown, from clinical odds to capital and manufacturing. ### FDA approval process explained A founder's guide from the IND to approval, including 351(a) biologics and expedited pathways. ### Why manufacturing is the real moat Why process and manufacturing, not the molecule alone, decide which healthcare companies win. ### What is modern cancer research? A plain-language guide to current approaches in oncology, for education only. View all featured insights → ## Three decades in FDA-regulated healthcare. Andrew Jonathan Hillman built and ran FDA-regulated healthcare companies for three decades before closing that operating career. He co-founded, operated, and exited companies across surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices. That operating experience now informs his healthcare compliance and expert-witness work. Hillman Ventures, his family office founded in 1995, remains private. The account of public filings, recognitions, and federal records is maintained at andrewhillmanrecord.com . Investment activity is detailed at Hillman Ventures , and community work at andrewhillman.org . ## Co-founded operating companies and strategic exits. A selection from 89+ ventures across three decades, with locations. The full portfolio and exits are documented on the record. ### Surgical hospitals & ambulatory centers ### Laboratories & pharmacy ### Devices, biologics & holdings Bone Solutions Incorporated logo View the full documented portfolio and exits → ## The essentials, on the record. Name Andrew Jonathan Hillman (Andrew J. Hillman). Dallas, Texas. Role Dallas Senior Paralegal and Healthcare Compliance Expert Witness, retained through counsel in federal matters nationwide. Not an attorney. See the healthcare compliance expert witness page . Family office Principal of Hillman Ventures, a private family office founded in 1995. Investment focus Frontier biotech for inflammation, damaged tissue, and tumor-based cancers. Operating record Three decades in FDA-regulated healthcare across surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices. 89+ ventures, 85+ strategic exits. Healthcare ownership Past owner and operator of a Class A retail pharmacy, a Class G administrative pharmacy, and a wholesale pharmacy distributor, and of ambulatory surgical centers, acute care hospitals, and a rehabilitation hospital. Now advancing breakthroughs in biotech drugs, technologies, and devices, harnessing these innovations to change medicine for the better. Also Author of The Hillman Letter on regulatory strategy and the Andrew Hillman Dallas blog , and strategic advisory at andrewhillmanadvisor.com . Public record Registered Texas lobbyist in 2001 ( Texas Ethics Commission lobby registry). Verification Independent, source-cited record at andrewhillmanrecord.com , profile at LinkedIn , Wikidata , ORCID , ResearchGate , and X . ## Publications, ORCID and Zenodo. Andrew Jonathan Hillman's works are listed on ORCID 0009-0001-5396-321X and deposited on Zenodo with permanent DOIs. - Wharton's Jelly MSC-Derived Exosomes in Spinal Disc Repair . Zenodo DOI 10.5281/zenodo.20978822 - Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly: The Gold Standard for Safe, Compliant Regenerative Medicine . Zenodo DOI 10.5281/zenodo.20974697 - Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tissue Repair Across Multiple Body Systems: A Narrative Review . Zenodo DOI 10.5281/zenodo.23574345 - The Biologics Paradigm: Wharton's Jelly Mesenchymal Exosomes as a Section 351(a) Drug vs. the Section 361 HCT/P pathway . Zenodo DOI 10.5281/zenodo.21142612 - Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications: A Structured Review . Zenodo DOI 10.5281/zenodo.21209815 - Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly Umbilical Cord: Regulatory Classification Under FDA CBER Section 351(a) . Zenodo DOI 10.5281/zenodo.21169929 Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment. ## The Hillman Letter Notes on healthcare regulatory strategy, compliance and enforcement. One issue a week. - Oct 19, 2026 The Spreadsheet Knew Two September and October settlements show how a stalled internal review turns into a False Claims Act case. The 60-day overpayment clock is the reason. - Oct 12, 2026 The Shred Bin Is Evidence Retention schedules and litigation holds are one system. Build it before the subpoena lands, not after. DOI: https://doi.org/10.5281/zenodo.23352303 - Oct 5, 2026 How to Write a Healthcare Compliance Expert Report That Survives Rule 702 The 2023 amendment moved gatekeeping from theory to practice. DOI: https://doi.org/10.5281/zenodo.23352301 - Sep 28, 2026 Pathway Diligence Before the Check Clears An operator checklist for family-office diligence before the wire. DOI: https://doi.org/10.5281/zenodo.23352299 - Sep 21, 2026 The R3 Medical Warning Letter Is a Pattern, Not a Mood What operators should extract from FDA warning-letter patterns in regenerative clinics. DOI: https://doi.org/10.5281/zenodo.23352297 - Sep 14, 2026 The Same Surgical Procedure Loophole Is Closed. Here Is What the Cell Surgical Network Injunction Means for Everyone Building a Cell or Exosome Product. Eight years, one reversal, and a nine-page order that ends the argument. - Sep 7, 2026 After the Tissue Grey Market Warning Letters, What Clinics Should Pressure-Test Before a CID Arrives A clinic-facing checklist for pressure-testing operations after tissue grey-market warning letters, before a CID arrives. DOI: https://doi.org/10.5281/zenodo.23352295 - Aug 31, 2026 What Retaining Counsel Actually Needs from an Operator Expert The designation is wasted if the role is fuzzy, the file is a theory, and the opinion is asked to outrun the operating record. DOI: https://doi.org/10.5281/zenodo.23352293 - Aug 16, 2026 The Permission Gap Twelve states rewrote regenerative medicine law in eighteen months. Federal law did not move. Here is what that costs you. DOI: https://doi.org/10.5281/zenodo.23352291 - Aug 11, 2026 Exosome trial halted after five patients (Aug 2026) The sponsor terminated its ExoFlo trial in perianal fistula (NCT05836883) on August 11. DOI: https://doi.org/10.5281/zenodo.23352289 - Aug 20, 2026 How to Build a Brand People Remember An eight-step operator checklist for distinctive, consistent brands in regulated healthcare and biotech. - Jun 11, 2026 The NextMed Settlement Is a Roadmap. Read It Before You Build the Next Telehealth Brand. The FTC handed the telehealth industry an inspection checklist. DOI: https://doi.org/10.5281/zenodo.23352265 - Jun 11, 2026 The Specific Pattern That Killed Five Biotech Programs I Personally Watched The pattern was the same across five programs. In case you are running one of the next ones. - Jun 10, 2026 Why Dallas Is Quietly Becoming the Right Place to Build FDA-Regulated Biotech The Dallas-Fort Worth biotech ecosystem has been compounding for three decades. - Jun 9, 2026 The 351 vs 361 Decision That Kills Most Exosome Programs Why most exosome programs pick the wrong FDA pathway, and what the BLA route actually demands. - Jun 8, 2026 Why Family Office Capital Fits FDA-Regulated Biotech Better Than Venture Money A ten-year venture fund has to return capital on a schedule. The FDA does not care about your schedule. - Jun 7, 2026 The Six Documentation Patterns That Show Up Before Federal Healthcare Enforcement Every enforcement action I have served on involved a pattern visible eighteen to thirty-six months before. - Jun 12, 2026 What Thirty Years of Operating in FDA-Regulated Healthcare Actually Taught Me Five lessons I would tell my younger self if I could. All issues on Substack ## Where the work goes now. ### Hillman Ventures Andrew Hillman's private family office. Its activities and holdings are kept private by design. ### Community & giving The Andrew Hillman Family Room at the Lamplighter School, the Scholarship for Entrepreneurs, and the Grant for Biotech. ### Writing This week's Hillman Letter: The Spreadsheet Knew. Notes on healthcare regulatory strategy, compliance, and enforcement. ## Healthcare deals, taken private and public. Andrew Hillman has helped take healthcare companies private and public, and has bought and sold healthcare businesses across multiple sectors. His portfolio includes Bone Solutions, Inc. (Southlake, Texas), an orthobiologics company with eight FDA 510(k) clearances. ### Taken private The Apothecary Shop pharmacies (formerly Over the Counter, OTC) and Digimed. ### Public markets Dynacq Healthcare (NASDAQ: DYII). The former Victory Hospitals, acquired by Nobilis Health Corp. (HLTH) . Vista Hospital (Dallas, Texas, Baton Rouge, Louisiana, and Houston, Texas), a past hospital ownership. Andrew Hillman states Vista Hospital ranked number 2 on a 2002 Forbes list. That distinction reflects his account and is not independently verified here. ### Bought & sold Medical groups, anesthesia groups, chiropractic groups, MRI and imaging centers, clinical laboratories, and pharmacies. ## A record you are free to check. Andrew Hillman's background is documented in a public record he also maintains, and in established identity registries. ## Published research. Andrew Hillman is the author of a white paper on Wharton's Jelly-derived mesenchymal stem cell exosomes, examining the underlying science, the FDA Section 351(a) biologic classification, cGMP manufacturing, and the regulatory pathway for cell-free regenerative medicine. ### Last Part Standing Andrew Jonathan Hillman, with Beverly Levine. A book by Andrew Jonathan Hillman, available in paperback and Kindle editions. Paperback ISBN 979-8184773162 · 58 pages · 2026 - Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications: A Structured Review of Published Preclinical and Early-Phase Clinical Study Designs, Administration Parameters, and Reported Outcomes , 2026. Structured review, CC BY 4.0, Zenodo. DOI: 10.5281/zenodo.21209815 . Indexed in OpenAIRE . · Official file - Wharton's Jelly Mesenchymal Stem Cell-Derived Exosomes: Dosing Protocols, Manufacturing Quality Systems, Drug Master File Requirements, cGMP Compliance, and the Complete Federal and State Regulatory Framework Under the FDA 351(a) CBER Pathway , 2026. Regulatory monograph, Academia.edu. Author Andrew J. Hillman (ORCID 0009-0001-5396-321X). Zenodo DOI pending. - Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tissue Repair Across Multiple Body Systems: A Narrative Review , 2026. Narrative review, CC BY 4.0, Zenodo. DOI: 10.5281/zenodo.23574345 . Indexed in OpenAIRE . · Official file - Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes , 2026. Short version. Listed on ORCID and Academia.edu. ### About DOIs and permanent links A DOI, or Digital Object Identifier, is a permanent identifier for a document. It always resolves at https://doi.org/ followed by the DOI, even when the file location changes. Each paper below with a DOI is citable by that DOI as its permanent link. OpenAIRE holds an independent backup record. - Wharton's Jelly MSC-Derived Exosomes in Spinal Disc Repair. Permanent DOI 10.5281/zenodo.20978822 . · Official file . OpenAIRE backup record . - MSC-Derived Extracellular Vesicles for Tissue Repair, a Narrative Review. Permanent DOI 10.5281/zenodo.23574345 . OpenAIRE backup record . - Wharton's Jelly MSC-Derived Exosomes, regulatory monograph on the FDA 351(a) CBER pathway. DOI pending. A permanent DOI will be added here once the Zenodo record is issued. Studies with official deposit files : andrew-hillman.com/studies . ## Giving back. Andrew Hillman enjoys mentoring young people in business, an interest that pairs naturally with the Andrew Hillman Scholarship for Entrepreneurs . He is also a donor to and supporter of community and charitable organizations, including the Altus Foundation in Houston, the charitable foundation affiliated with ZT Corporate. He also supports the Heroes for Israel Project , a 501(c)(3) nonprofit supporting Israel's border communities and volunteer first responders, with a $100,000 gift in 2025. ## A record, year by year. Dated, verifiable milestones in community giving. Each entry is documented on this site or a third-party record. - 2017 KidSwing 2017 sponsorship A June 28, 2017 KidSwing letter documents an $18,000 sponsorship for KidSwing 2017, benefiting Texas Scottish Rite Hospital for Children. See andrewhillman.org/#kidswing . - 2018 Hillman Family Room established at The Lamplighter School A $300,000 gift established the Hillman Family Room at The Lamplighter School in Dallas. The Hillman Family Room is a named technology and robotics space for students. - 2020 to 2026 Annual gifts to Parish Episcopal School Annual donations to Parish Episcopal School in Dallas, Texas, every year from 2020 through 2026. ## Education giving. - The Lamplighter School , Dallas, Texas. More than $500,000 in cumulative gifts, including the $300,000 Hillman Family Room. - Parish Episcopal School , Dallas, Texas. Annual donations every year from 2020 through 2026. ## On the record. Total giving, The Lamplighter School More than $500,000 in cumulative gifts to The Lamplighter School in Dallas, Texas, including the $300,000 Hillman Family Room. Hillman Family Room A $300,000 gift in 2018 established the Hillman Family Room at The Lamplighter School in Dallas. The Hillman Family Room is a named technology and robotics space for students. Parish Episcopal School Annual donations to Parish Episcopal School in Dallas, Texas, every year from 2020 through 2026. Location The Lamplighter School, Dallas, Texas. The complete community and giving record, including organizations beyond the schools listed here, is maintained at andrewhillman.org . Figures shown are cumulative gift totals as confirmed by Andrew Hillman. Amounts are not published for every organization supported. ## Life beyond the work. A proud American, he keeps a disciplined, drug-free and alcohol-free routine built around the gym, the Katy Trail, and road and pedal cycling. Colorado, Dorado and Puerto Rico are among the places that have shaped a long career. Andrew Hillman in Coral Gables, Florida Dorado, Puerto Rico Miami Beach Road cycling in Dallas, Texas Victory Medical Center San Antonio. Address 4243. Past ownership. Victory Medical Center San Antonio. Architectural rendering. Past ownership. Victory Medical Center recovery room. Past ownership. Victory Medical Center groundbreaking. Past ownership. Victory Medical Center Beaumont open house. Past ownership. Victory Medical Center. Past ownership. Victory Medical Center Mid Cities. Past ownership. Victory Medical Center lobby. Victory Medical Center Mid Cities wall sign. Past ownership. In Colorado Victory grand opening, Craig Ranch, McKinney Victory Healthcare Services, LLC. Past ownership. Victory Medical Center Beaumont. Past ownership. Enjoying the outdoors Andrew Hillman at CORE hospital, Tijuana, Mexico On a podcast. With friends. At a bioskills laboratory. At CORE hospital, Tijuana, Mexico. The ceremony of the signing of CORE hospital with Cedars Sinai. Surgery Specialty Hospitals of America. Past ownership. The Texas Clinic at Prestonwood, Plano, Texas. Past ownership. Andrew Hillman. 5710 and 5728 LBJ Freeway, Dallas. Office interior. Andrew Hillman. 5710 and 5728 LBJ Freeway, Dallas. Indoor golf simulator. Andrew Hillman. 5710 and 5728 LBJ Freeway, Dallas. Fitness center. Andrew Hillman. 5710 and 5728 LBJ Freeway, Dallas. Building lounge. Andrew Hillman with others. Andrew Hillman in Dallas. Select any photo to view it larger. Use the arrow keys or swipe to browse. Former Victory Hospitals were later acquired by Nobilis Health. These Victory photos are past ownership. ## Andrew Hillman, answered. Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment. Andrew Hillman of Dallas, Texas is also known as Andrew Jonathan Hillman, Andrew J. Hillman, Andy Hillman, and A.J. Hillman. One person, one official network. Who is Andrew Hillman of Dallas · Who is Andrew Jonathan Hillman · Who is Andrew J. Hillman · Who is Andy Hillman · Who is A.J. Hillman · Andrew Hillman biography · Andrew Jonathan Hillman resume ## Profiles and identifiers - LinkedIn LinkedIn Professional profile - ORCID Researcher ID 0009-0001-5396-321X - Wikidata Entity Q139969699 - Google Scholar Google Scholar Citations and papers - Academia.edu Papers and monographs - Zenodo Deposited works with DOIs - X @AndrewHillmanTX - TikTok @ajhusa - Pinterest AndrewJHillmanTexas - Telegram @AJHUSA - Instagram @andrewhillmandallas - The Hillman Letter The Hillman Letter Weekly letter on Substack - Amazon Last Part Standing, paperback Dallas senior paralegal and healthcare compliance expert witness. Not an attorney. Expert witness page · Publications ## Profiles - LinkedIn - ORCID - Wikidata - Google Scholar - Academia.edu - X - TikTok - Pinterest - Telegram - Instagram - Book a meeting - The Hillman Letter ## Press - The Tennessean - Yahoo Finance - EIN Presswire ## Sites - Hub - Expert witness - Giving - Advisory - Hillman Ventures - Public record © 2026 Andrew Jonathan Hillman, Dallas, Texas. Information on this site is provided for general informational purposes and is believed accurate as of publication. Views expressed are my own. Owner. Andrew Jonathan Hillman, Dallas, Texas. Purpose. Document the healthcare compliance and expert-witness work of Andrew Hillman, and his three decades of prior operating history in FDA-regulated healthcare before closing that operating career. What this site is not. This site is not advisory, investment, or legal interpretation. It does not offer services, solicit capital, or provide legal advice. Primary audience. Journalists, researchers, prospective partners, and anyone verifying the professional background of Andrew Hillman. Last updated: July 12, 2026, 10:48 PM CT The work follows three convictions: regulatory compliance is the foundation of durable healthcare operations, documented evidence outweighs narrative, and long relationships compound over time. Surgical hospitals and ambulatory surgical centers. Clinical and toxicology laboratories. Pharmacy operations. Medical devices. FDA-regulated biologics and regenerative medicine. Healthcare transactions and exits. This site presents prior operating history and current healthcare compliance and expert-witness work. It is not advisory, investment, or legal interpretation. For advisory work see andrewhillmanadvisor.com. For investment activity see hillmanv.com. For the documented public record see andrewhillmanrecord.com. - Andrew Jonathan Hillman is a Dallas, Texas senior paralegal and healthcare compliance and regulatory expert witness, retained through counsel, and the principal of Hillman Ventures, a private family office founded in 1995. - His operating history spans surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices. - The published record references more than 89 ventures and more than 85 strategic exits. - Current work is healthcare compliance and regulatory matters, as a senior paralegal and expert witness retained through counsel, covering regulatory governance, internal investigations, data privacy, and litigation support. - Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment. - Hillman Ventures, his private family office, keeps its activities and holdings private by design. - Giving includes more than $500,000 in cumulative gifts to The Lamplighter School, including the $300,000 Hillman Family Room. - Giving includes annual donations to Parish Episcopal School in Dallas, Texas, every year from 2020 through 2026. - Andrew Hillman also maintains a public record at andrewhillmanrecord.com. [source] - Identity is registered in public databases including Wikidata, ORCID, LinkedIn, and X. [source] This site is one component of a multi-domain ecosystem. Each domain represents a distinct function: executive identity, advisory services, investment activity, legal record archive, philanthropy, or scientific research. Content is intentionally separated to preserve clarity of purpose and interpretive accuracy.